Drug Profile


Alternative Names: AERAS-485; MVA-85A; MVA-85A-IMX-313; Tuberculosis subunit vaccine - Emergent BioSolutions/University of Oxford; Tuberculosis vaccine - University of Oxford

Latest Information Update: 04 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Oxford
  • Developer Aeras; University of Oxford
  • Class Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 21 Aug 2015 The University of Oxford plans a phase I trial for Tuberculosis in the United Kingdom (UKCRN19306)
  • 15 Dec 2014 University of Oxford completes a phase I trial in Tuberculosis (Prevention) in United Kingdom (NCT01879163)
  • 01 Sep 2014 Oxford-Emergent Tuberculosis Consortium and Aeras complete a phase II trial in Tuberculosis (prevention, in adults with HIV infection) in Senegal and South Africa (NCT01151189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top